** J.P.Morgan initiates coverage on life sciences company
Seer Inc SEER.O with "overweight" rating and PT of $75
** JPM says Seer is an industry pioneer in proteomic
analysis with a unique and disruptive technology that enables
unbiased, deep, rapid, large-scale proteomics to accelerate
biological insights
** Brokerage says co's large TAM (total addressable market)
of more than $50 bln and low adoption hurdles poised to drive a
proteomics revolution
** Co has multiple drivers which can sustain a 45%+ growth
with operating leverage promising significant margin potential -
JPM
** JPM expects co's revenue CAGR (compounded annual growth
rate) to be +191% over 2020-25 and +45% over 2025-30,
representing the best growth profile within the brokerage's
coverage
** Says co's instrument sales are expected to carry a 35%
long-term gross margin, while consumables sales are likely to
carry a much higher 75%-80%+
** On Dec. 4, co announced the pricing of its IPO of 9.2 mln
shares of class A common stock at $19 per share urn:newsml:reuters.com:*:nASA01H00
(Reporting by Aniruddha Chakrabarty)
((aniruddha.c.thomsonreuters.com@reuters.net))